Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Enterprise Value to EBITDA (EV/EBITDA)

Microsoft Excel

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

Allergan Inc., EBITDA calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Net earnings attributable to Allergan, Inc. 1,524,200 985,100 1,098,800 934,500 600
Add: Net income attributable to noncontrolling interest 4,600 3,600 3,700 3,600 4,300
Less: Discontinued operations (3,800) (283,800)
Add: Income tax expense 456,700 458,300 430,800 361,600 165,900
Earnings before tax (EBT) 1,989,300 1,730,800 1,533,300 1,299,700 170,800
Add: Interest expense 69,400 75,000 63,600 71,800 78,700
Earnings before interest and tax (EBIT) 2,058,700 1,805,800 1,596,900 1,371,500 249,500
Add: Depreciation and amortization 248,100 254,600 256,600 253,400 257,100
Earnings before interest, tax, depreciation and amortization (EBITDA) 2,306,800 2,060,400 1,853,500 1,624,900 506,600

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

Item Description The company
EBITDA To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. Allergan Inc. EBITDA increased from 2012 to 2013 and from 2013 to 2014.

Enterprise Value to EBITDA Ratio, Current

Allergan Inc., current EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in thousands)
Enterprise value (EV) 66,591,934
Earnings before interest, tax, depreciation and amortization (EBITDA) 2,306,800
Valuation Ratio
EV/EBITDA 28.87
Benchmarks
EV/EBITDA, Competitors1
AbbVie Inc. 19.98
Amgen Inc. 13.47
Bristol-Myers Squibb Co. 6.55
Eli Lilly & Co. 83.72
Gilead Sciences Inc. 9.63
Johnson & Johnson 15.68
Merck & Co. Inc. 50.60
Pfizer Inc. 21.74
Regeneron Pharmaceuticals Inc. 19.32
Thermo Fisher Scientific Inc. 21.41
Zoetis Inc. 19.41

Based on: 10-K (reporting date: 2014-12-31).

1 Click competitor name to see calculations.

If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.


Enterprise Value to EBITDA Ratio, Historical

Allergan Inc., historical EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Selected Financial Data (US$ in thousands)
Enterprise value (EV)1 66,591,936 35,980,729 30,534,136 26,076,707 21,771,762
Earnings before interest, tax, depreciation and amortization (EBITDA)2 2,306,800 2,060,400 1,853,500 1,624,900 506,600
Valuation Ratio
EV/EBITDA3 28.87 17.46 16.47 16.05 42.98
Benchmarks
EV/EBITDA, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Zoetis Inc.

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

1 See details »

2 See details »

3 2014 Calculation
EV/EBITDA = EV ÷ EBITDA
= 66,591,936 ÷ 2,306,800 = 28.87

4 Click competitor name to see calculations.

Valuation ratio Description The company
EV/EBITDA Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. Allergan Inc. EV/EBITDA ratio increased from 2012 to 2013 and from 2013 to 2014.